Margie Danchin1, Ruby Biezen2, Jo-Anne Manski-Nankervis3, Jessica Kaufman4, Julie Leask5. 1. MBBS, PhD, FRACP, Associate Professor and David Bickart Clinician Scientist Fellow, Department of Paediatrics, The University of Melbourne, Vic; Group Leader, Vaccine Uptake Group, Murdoch Children@s Research Institute, Vic; Paediatrician, Department of General Medicine, The Royal Children@s Hospital, Vic. 2. MAppSc, PhD, Research Fellow, Department of General Practice, Melbourne Medical School, University of Melbourne, Vic. 3. BSc (Hons), MBBS (Hons), CHIA, PhD, FRACGP, Associate Professor - General Practice, Melbourne Medical School, University of Melbourne, Vic. 4. PhD, Research Fellow, Vaccine Uptake Group, Murdoch Children@s Research Institute, Vic; Honorary Fellow, Department of Paediatrics, The University of Melbourne, Vic. 5. PhD, MPH, Dip Health Sci (Nursing), Professor, Susan Wakil School of Nursing and Midwifery, Faculty of Medicine and Health, The University of Sydney, NSW; Visiting Professorial Fellow, National Centre for Immunisation Research and Surveillance, NSW.
Abstract
BACKGROUND: The availability of a COVID-19 vaccine is being heralded as the solution to control the current COVID-19 pandemic, reduce the number of infections and deaths and facilitate resumption of our previous way of life. OBJECTIVE: The aim of this article is to provide a framework for primary care of what will be needed to optimise COVID-19 vaccine confidence and uptake in Australia once the vaccine prioritisation schedule and key target groups are known. DISCUSSION: While a number of vaccines are currently under development, with at least seven undergoing phase III trials (28 August 2020), it is hoped that an effective COVID-19 vaccine will become available to the public in 2021. Ensuring public confidence in vaccine safety and effectiveness will be crucial to facilitate uptake. General practitioners are at the forefront of public health, and one of the most trusted sources for patients. In this article, the authors discuss the expedited vaccine development process for COVID-19 vaccines; the likely vaccine prioritisation schedule and anticipated key target groups; the behavioural and social drivers of vaccination acceptance, including the work required to facilitate this; and the implications for general practice.
BACKGROUND: The availability of a COVID-19 vaccine is being heralded as the solution to control the current COVID-19 pandemic, reduce the number of infections and deaths and facilitate resumption of our previous way of life. OBJECTIVE: The aim of this article is to provide a framework for primary care of what will be needed to optimise COVID-19 vaccine confidence and uptake in Australia once the vaccine prioritisation schedule and key target groups are known. DISCUSSION: While a number of vaccines are currently under development, with at least seven undergoing phase III trials (28 August 2020), it is hoped that an effective COVID-19 vaccine will become available to the public in 2021. Ensuring public confidence in vaccine safety and effectiveness will be crucial to facilitate uptake. General practitioners are at the forefront of public health, and one of the most trusted sources for patients. In this article, the authors discuss the expedited vaccine development process for COVID-19 vaccines; the likely vaccine prioritisation schedule and anticipated key target groups; the behavioural and social drivers of vaccination acceptance, including the work required to facilitate this; and the implications for general practice.
Authors: Joanne Enticott; Jaskirath Singh Gill; Simon L Bacon; Kim L Lavoie; Daniel S Epstein; Shrinkhala Dawadi; Helena J Teede; Jacqueline Boyle Journal: BMJ Open Date: 2022-01-03 Impact factor: 2.692
Authors: Noelia Rodríguez-Blanco; Sergio Montero-Navarro; José M Botella-Rico; Antonio J Felipe-Gómez; Jesús Sánchez-Más; José Tuells Journal: Int J Environ Res Public Health Date: 2021-05-15 Impact factor: 3.390